Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Approval for Acetazolamide Extended-Release Capsules, 500 mg. Further, the company has submitted its press release.
The above information is a part of company’s filings submitted to BSE.